Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals Inc (NQ: PIRS )

9.480 +0.760 (+8.72%)
Streaming Delayed Price Updated: 3:50 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
What's Going On With Pieris Pharmaceuticals Stock Today?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are tradin... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Rezolute (NASDAQ:RZLT) shares rose 46.68% to $11.28 during Thursday's regular session. As of 12:30 EST, Rezolute's stock is trading at a volume of 1.4... 
Via Benzinga
41 Stocks Moving In Thursday's Mid-Day Session
Gainers 1847 Goedeker Inc. (NYSE: GOED) shares jumped 156.5% to $11.08 after dropping over 8% on Wednesday. Vertex Energy, Inc. (NASDAQ: VTNR) jumped 117% to $3.8604 after the... 
Via Benzinga
PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today
Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech. 
Via InvestorPlace
Pieris Pharmaceuticals Surges On The Stock Market After Agreement With Genentech
During yesterday's session, Pieris Pharmaceuticals (PIRS) soared in the financial markets after reaching a collaboration agreement with Genentech, in an operation that could be valued at $1.4 billion. 
Via Talk Markets
Where Will The Pieris Pharmacuetical Stock Rally End?
Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on Tu... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 20.74% to $4.54 during Wednesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV) rose 48.8% to $2.20 in pre-market trading. Sinovant Sciences and Nabriva Therapeutics disclosed topline results from Phase 3 trial... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS 
Via Benzinga
Stocks Stunted Midday as Reopening Plays Weaken
The major indexes have pared most of their pre-market gains, giving way to a somewhat static afternoon. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's... 
Via Benzinga
Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) shares increased by 27.99% to $5.99 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
- Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs -... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals: Q1 Earnings Insights
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 0.00% over the past... 
Via Benzinga
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT - PRS-060/AZD1402 dosed to first patient in phase 2a study - Cinrebafusp alfa (PRS-343) phase 2 study expected to... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Earnings Scheduled For May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
Exposures Product Safety
Earnings Preview: Pieris Pharmaceuticals
On Monday, May 17, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release... 
Via Benzinga
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
- Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties - Boston Pharmaceuticals will be primarily responsible for development of the... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.